Delavirdine
Non-nucleoside reverse transcriptase inhibitors bind an allosteric pocket on HIV reverse transcriptase, and delavirdine was among the first generation of that class. Inhibiting the enzyme halts transcription of viral RNA into DNA and blocks replication in infected cells, an effect deployed as part of combination antiretroviral therapy rather than as monotherapy. More potent and better-tolerated NNRTIs have since displaced it from routine regimens, so its present significance is largely historical within the development of HIV treatment. Chemically it is a small molecule of formula C22H28N6O3S with a mass close to 456.6 g/mol. The agent is approved and completed the final phase of clinical development.
A non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by binding to and inhibiting reverse transcriptase, used as part of combination antiretroviral therapy. It has been largely replaced by more potent and better-tolerated NNRTIs.
Molecular Weight
456.6000 g/mol
LogP
2.40
TPSA
119.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1
InChI
InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
Molecular Formula
C22H28N6O3S
HBD / HBA
3 / 7
Rotatable Bonds
6
Heavy Atoms
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by binding to and inhibiting reverse transcriptase, used as part of combination antiretroviral therapy. It has been largely replaced by more potent and better-tolerated NNRTIs.
Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.
Yes, Delavirdine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL593. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5625. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="delavirdine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/delavirdine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/delavirdine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/delavirdine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="delavirdine"></drugfyi-drug>